Roche said today it will acquire Trophos for up to €470 million (about $543 million), in a deal that will expand the pharma giant’s portfolio in neuromuscular disease with high medical need, anchored by the Phase II/III-completed spinal muscular atrophy (SMA) compound olesoxime (TRO19622).